Nissei Bilis Co.,Ltd.

Nissei Bilis Co., Ltd. (hereinafter referred to as Nissei Bilis) conducts studies across multiple disease areas with an emphasis on pharmacology/pharmacodynamics (PD) studies. This overview describes the features of the company’s nonclinical studies, examples of disease models, and case studies. Please use this as a reference when selecting a contract research partner.

Features of Nissei Bilis Co.,Ltd.’ Non-Clinical Contract Research Services

Comprehensive toxicity studies

Nissei Bilis Co.,Ltd. provides a range of toxicity studies—including acute, subacute, and chronic studies—enabling comprehensive safety evaluation of pharmaceuticals and medical devices. The company also conducts tumorigenicity tests using immunodeficient mice and cytotoxicity assays to characterize drug effects in detail.

Biocompatibility Testing

Nissei Bilis Co.,Ltd. an extensive menu of biological safety/biocompatibility tests, including skin irritation, sensitization, and genotoxicity. The team supports safety evaluations for medical devices and regenerative medical products. Assessments are performed under conditions aligned with intended use—for example, implantation and hemocompatibility evaluations—to generate reliable data.

Use of advanced animal models

Nissei Bilis Co.,Ltd. conducts nonclinical studies using advanced animal models, such as myocardial infarction and stroke models, enabling evaluation of new drugs’ efficacy and safety in disease-relevant contexts. The company also performs general toxicity and tumorigenicity studies using severely immunodeficient animals, which support development of therapies for specific diseases.

Representative Disease Models at Nissei Bilis Co.,Ltd.

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Cerebral infarction and cerebral edema models

Models include Mongolian gerbils and rats with bilateral common carotid artery occlusion (BCCAO); mice and rats with middle cerebral artery occlusion (MCAO) using the nylon-filament method with ischemia–reperfusion; rats with four-vessel occlusion (4-VO); and young rats with perinatal hypoxic–ischemic encephalopathy.

Heart failure models

Models include pacing-induced heart failure (dog); low-output acute heart failure (dog); propranolol-induced heart failure (dog); J2N-k hamster (dilated cardiomyopathy); and porcine myosin–induced myocarditis (rat).

Non-Clinical case examples at Nissei Bilis Co.,Ltd.

No case studies are currently listed on the official website.

Corporate information

Nissei Bilis Co.,Ltd. operates two primary divisions: the Trading Division, which sells raw materials for chemicals, pharmaceuticals, and food products; and the Contract Business Division, which conducts nonclinical studies. The Contract Business Division contributes to healthcare and human health through pharmacology/pharmacodynamics (PD) and safety testing.